Literature DB >> 28885378

Radial Force: An Underestimated Parameter in Oversizing Transcatheter Aortic Valve Replacement Prostheses: In Vitro Analysis with Five Commercialized Valves.

Sandrine Egron1, Buntaro Fujita2, Lucía Gullón1, Désirée Pott1, Thomas Schmitz-Rode1, Stephan Ensminger2, Ulrich Steinseifer1.   

Abstract

The goal is to inform in depth on transcatheter aortic valve replacement (TAVR) prosthesis mechanical behavior, depending on frame type, design, and size, and how it crucially impacts the oversizing issue in clinical use, and ultimately the procedure outcome. Transcatheter aortic valve replacement is an established therapy for high-risk patients suffering from aortic stenosis, and the indication for TAVR is progressively expanding to intermediate-risk patients. Choosing the optimal oversizing degree is crucial to safely anchor the TAVR valve-which involves limiting the risks for embolism, aortic regurgitation, conductance disturbance, or annulus rupture-and to increase the valve prosthesis performance. The radial force (RF) profiles of five TAVR prostheses were measured in vitro: the CoreValve 23 and 26 (Medtronic, Minneapolis, MN), the Acurate neo S (Symetis, Écublens, Vaud, Switzerland), and the SAPIEN XT 23 and 26 (Edwards Lifesciences, Irvine, CA). Measurements were run with the RX Machine equipment (Machine Solutions Inc., Flagstaff, AZ), which is used in ISO standard tests for intravascular stents. Test protocols were adapted for TAVR prostheses. With the prostheses RF profiles' results, mechanical behavior differences could be described and discussed in terms of oversizing strategy and clinical impact for all five valves. Besides, crossing the prostheses' RF profiles with their recommended size windows made the assessment of borderline size cases possible and helped analyze the risks when accurate measurement of patient aortic annulus proves difficult. The prostheses' RF profiles bring new support in clinical decision-making for valve type and size in patients.

Entities:  

Mesh:

Year:  2018        PMID: 28885378     DOI: 10.1097/MAT.0000000000000659

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  6 in total

1.  The impact of balloon-expandable transcatheter aortic valve replacement on concomitant mitral regurgitation: a comprehensive computational analysis.

Authors:  Andrés Caballero; Wenbin Mao; Raymond McKay; Wei Sun
Journal:  J R Soc Interface       Date:  2019-08-14       Impact factor: 4.118

Review 2.  Principles of TAVR valve design, modelling, and testing.

Authors:  Oren M Rotman; Matteo Bianchi; Ram P Ghosh; Brandon Kovarovic; Danny Bluestein
Journal:  Expert Rev Med Devices       Date:  2018-10-29       Impact factor: 3.166

3.  Designing a Novel Asymmetric Transcatheter Aortic Valve for Stenotic Bicuspid Aortic Valves Using Patient-Specific Computational Modeling.

Authors:  Ryan T Helbock; Salwa B Anam; Brandon J Kovarovic; Marvin J Slepian; Ashraf Hamdan; Rami Haj-Ali; Danny Bluestein
Journal:  Ann Biomed Eng       Date:  2022-08-30       Impact factor: 4.219

4.  The Impact of Self-Expandable Transcatheter Aortic Valve Replacement on Concomitant Functional Mitral Regurgitation: A Comprehensive Engineering Analysis.

Authors:  Andrés Caballero; Wenbin Mao; Raymond McKay; Wei Sun
Journal:  Struct Heart       Date:  2020-04-03

5.  Low Rates of Permanent Pacing Are Observed Following Self-Expanding Transcatheter Aortic Valve Replacement Using an Annular Plane Projection for Deployment.

Authors:  Anthony D Pisaniello; Haytham B E Makki; Saleem Jahangeer; Matthew J Daniels; Ragheb Hasan; Douglas G W Fraser
Journal:  Circ Cardiovasc Interv       Date:  2021-01-12       Impact factor: 6.546

6.  The use of semi-compliant versus non-compliant balloon systems for predilatation during the implantation of self-expandable transcatheter aortic valves: Data from the VIenna CardioThOracic Aortic Valve RegistrY (VICTORY).

Authors:  Markus Mach; Philipp Szalkiewicz; Thomas Poschner; Waseem Hasan; Martin Andreas; Bernhard Winkler; Ena Hasimbegovic; Theresia Steinkellner; Andreas Strouhal; Christopher Adlbrecht; Georg Delle-Karth; Martin Grabenwöger
Journal:  Eur J Clin Invest       Date:  2021-05-06       Impact factor: 4.686

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.